APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Myasthenia Gravis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Myasthenia Gravis Drugs Market Outlook and Growth Opportunities 2026

Report ID 174015120426 December 2025208 pages

Choose your research edition.

Industry ResearchMyasthenia Gravis Drugs Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Myasthenia Gravis Drugs Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Myasthenia Gravis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Myasthenia Gravis Drugs Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Myasthenia Gravis Drugs Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Myasthenia Gravis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Myasthenia Gravis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Myasthenia Gravis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Myasthenia Gravis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Myasthenia Gravis Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Myasthenia Gravis Drugs market include Alexion Pharmaceuticals, Bausch Health, Catalyst Pharmaceuticals, CSL, Curavac, Cytokinetics, F. Hoffmann-La Roche, Flamel Technologies and Galencia, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Myasthenia Gravis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Myasthenia Gravis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Myasthenia Gravis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Myasthenia Gravis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Myasthenia Gravis Drugs Segment by Company

Alexion Pharmaceuticals

Bausch Health

Catalyst Pharmaceuticals

CSL

Curavac

Cytokinetics

F. Hoffmann-La Roche

Flamel Technologies

Galencia

GlaxoSmithKline

Grifols

Lupin Pharmaceuticals

Mitsubishi Tanabe Pharma

Pfizer

Novartis

Takeda

Myasthenia Gravis Drugs Segment by Type

Intravenous Immune Globulins

Anticholinesterases

Immunosuppressants

Myasthenia Gravis Drugs Segment by Application

Hospitals

Clinics

Myasthenia Gravis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Myasthenia Gravis Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Myasthenia Gravis Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Myasthenia Gravis Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Myasthenia Gravis Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Myasthenia Gravis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Myasthenia Gravis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Myasthenia Gravis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Myasthenia Gravis Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Myasthenia Gravis Drugs industry.

Chapter 3: Detailed analysis of Myasthenia Gravis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Myasthenia Gravis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Myasthenia Gravis Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Myasthenia Gravis Drugs Industry Trends Table 2. Myasthenia Gravis Drugs Industry Drivers Table 3. Myasthenia Gravis Drugs Industry Opportunities and Challenges Table 4. Myasthenia Gravis Drugs Industry Restraints Table 5. Global Myasthenia Gravis Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Myasthenia Gravis Drugs Revenue Share by Company (2021-2026) Table 7. Global Myasthenia Gravis Drugs Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Myasthenia Gravis Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Myasthenia Gravis Drugs Average Price (US$/Kg) of Company (2021-2026) Table 10. Global Myasthenia Gravis Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Myasthenia Gravis Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Myasthenia Gravis Drugs Company, Product Type & Application Table 13. Global Myasthenia Gravis Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Myasthenia Gravis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Intravenous Immune Globulins Table 18. Significant Companies of Anticholinesterases Table 19. Significant Companies of Immunosuppressants Table 20. Global Myasthenia Gravis Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 21. Global Myasthenia Gravis Drugs Sales Volume by Type (2021-2026) & (Tons) Table 22. Global Myasthenia Gravis Drugs Sales Volume by Type (2027-2032) & (Tons) Table 23. Global Myasthenia Gravis Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Myasthenia Gravis Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Myasthenia Gravis Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Myasthenia Gravis Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Myasthenia Gravis Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Myasthenia Gravis Drugs Sales Value Share by Type (2021-2026) Table 29. Global Myasthenia Gravis Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospitals Table 31. Significant Companies of Clinics Table 32. Global Myasthenia Gravis Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 33. Global Myasthenia Gravis Drugs Sales Volume by Application (2021-2026) & (Tons) Table 34. Global Myasthenia Gravis Drugs Sales Volume by Application (2027-2032) & (Tons) Table 35. Global Myasthenia Gravis Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Myasthenia Gravis Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Myasthenia Gravis Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Myasthenia Gravis Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Myasthenia Gravis Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Myasthenia Gravis Drugs Sales Value Share by Application (2021-2026) Table 41. Global Myasthenia Gravis Drugs Sales Value Share by Application (2027-2032) Table 42. Global Myasthenia Gravis Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 43. Global Myasthenia Gravis Drugs Sales by Region (2021-2026) & (Tons) Table 44. Global Myasthenia Gravis Drugs Sales Market Share by Region (2021-2026) Table 45. Global Myasthenia Gravis Drugs Sales by Region (2027-2032) & (Tons) Table 46. Global Myasthenia Gravis Drugs Sales Market Share by Region (2027-2032) Table 47. Global Myasthenia Gravis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Myasthenia Gravis Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Myasthenia Gravis Drugs Sales Value Share by Region (2021-2026) Table 50. Global Myasthenia Gravis Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Myasthenia Gravis Drugs Sales Value Share by Region (2027-2032) Table 52. Global Myasthenia Gravis Drugs Market Average Price (US$/Kg) by Region (2021-2026) Table 53. Global Myasthenia Gravis Drugs Market Average Price (US$/Kg) by Region (2027-2032) Table 54. Global Myasthenia Gravis Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 55. Global Myasthenia Gravis Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Myasthenia Gravis Drugs Sales by Country (2021-2026) & (Tons) Table 57. Global Myasthenia Gravis Drugs Sales Market Share by Country (2021-2026) Table 58. Global Myasthenia Gravis Drugs Sales by Country (2027-2032) & (Tons) Table 59. Global Myasthenia Gravis Drugs Sales Market Share by Country (2027-2032) Table 60. Global Myasthenia Gravis Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Myasthenia Gravis Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Myasthenia Gravis Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Myasthenia Gravis Drugs Sales Value Market Share by Country (2027-2032) Table 64. Alexion Pharmaceuticals Company Information Table 65. Alexion Pharmaceuticals Business Overview Table 66. Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 67. Alexion Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio Table 68. Alexion Pharmaceuticals Recent Development Table 69. Bausch Health Company Information Table 70. Bausch Health Business Overview Table 71. Bausch Health Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 72. Bausch Health Myasthenia Gravis Drugs Product Portfolio Table 73. Bausch Health Recent Development Table 74. Catalyst Pharmaceuticals Company Information Table 75. Catalyst Pharmaceuticals Business Overview Table 76. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 77. Catalyst Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio Table 78. Catalyst Pharmaceuticals Recent Development Table 79. CSL Company Information Table 80. CSL Business Overview Table 81. CSL Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 82. CSL Myasthenia Gravis Drugs Product Portfolio Table 83. CSL Recent Development Table 84. Curavac Company Information Table 85. Curavac Business Overview Table 86. Curavac Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 87. Curavac Myasthenia Gravis Drugs Product Portfolio Table 88. Curavac Recent Development Table 89. Cytokinetics Company Information Table 90. Cytokinetics Business Overview Table 91. Cytokinetics Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 92. Cytokinetics Myasthenia Gravis Drugs Product Portfolio Table 93. Cytokinetics Recent Development Table 94. F. Hoffmann-La Roche Company Information Table 95. F. Hoffmann-La Roche Business Overview Table 96. F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 97. F. Hoffmann-La Roche Myasthenia Gravis Drugs Product Portfolio Table 98. F. Hoffmann-La Roche Recent Development Table 99. Flamel Technologies Company Information Table 100. Flamel Technologies Business Overview Table 101. Flamel Technologies Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 102. Flamel Technologies Myasthenia Gravis Drugs Product Portfolio Table 103. Flamel Technologies Recent Development Table 104. Galencia Company Information Table 105. Galencia Business Overview Table 106. Galencia Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 107. Galencia Myasthenia Gravis Drugs Product Portfolio Table 108. Galencia Recent Development Table 109. GlaxoSmithKline Company Information Table 110. GlaxoSmithKline Business Overview Table 111. GlaxoSmithKline Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 112. GlaxoSmithKline Myasthenia Gravis Drugs Product Portfolio Table 113. GlaxoSmithKline Recent Development Table 114. Grifols Company Information Table 115. Grifols Business Overview Table 116. Grifols Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 117. Grifols Myasthenia Gravis Drugs Product Portfolio Table 118. Grifols Recent Development Table 119. Lupin Pharmaceuticals Company Information Table 120. Lupin Pharmaceuticals Business Overview Table 121. Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 122. Lupin Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio Table 123. Lupin Pharmaceuticals Recent Development Table 124. Mitsubishi Tanabe Pharma Company Information Table 125. Mitsubishi Tanabe Pharma Business Overview Table 126. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 127. Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product Portfolio Table 128. Mitsubishi Tanabe Pharma Recent Development Table 129. Pfizer Company Information Table 130. Pfizer Business Overview Table 131. Pfizer Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 132. Pfizer Myasthenia Gravis Drugs Product Portfolio Table 133. Pfizer Recent Development Table 134. Novartis Company Information Table 135. Novartis Business Overview Table 136. Novartis Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 137. Novartis Myasthenia Gravis Drugs Product Portfolio Table 138. Novartis Recent Development Table 139. Takeda Company Information Table 140. Takeda Business Overview Table 141. Takeda Myasthenia Gravis Drugs Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 142. Takeda Myasthenia Gravis Drugs Product Portfolio Table 143. Takeda Recent Development Table 144. Key Raw Materials Table 145. Raw Materials Key Suppliers Table 146. Myasthenia Gravis Drugs Distributors List Table 147. Myasthenia Gravis Drugs Customers List Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Myasthenia Gravis Drugs Product Image Figure 2. Global Myasthenia Gravis Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Myasthenia Gravis Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Myasthenia Gravis Drugs Sales (2021-2032) & (Tons) Figure 5. Global Myasthenia Gravis Drugs Sales Average Price (US$/Kg) & (2021-2032) Figure 6. Global Myasthenia Gravis Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Intravenous Immune Globulins Image Figure 10. Anticholinesterases Image Figure 11. Immunosuppressants Image Figure 12. Global Myasthenia Gravis Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 13. Global Myasthenia Gravis Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Myasthenia Gravis Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Myasthenia Gravis Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Myasthenia Gravis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Myasthenia Gravis Drugs Sales Value Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Clinics Image Figure 20. Global Myasthenia Gravis Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 21. Global Myasthenia Gravis Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Myasthenia Gravis Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Myasthenia Gravis Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Myasthenia Gravis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Myasthenia Gravis Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Myasthenia Gravis Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 27. Global Myasthenia Gravis Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Myasthenia Gravis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Myasthenia Gravis Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Myasthenia Gravis Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Myasthenia Gravis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Myasthenia Gravis Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Myasthenia Gravis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Myasthenia Gravis Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Myasthenia Gravis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Myasthenia Gravis Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Myasthenia Gravis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Myasthenia Gravis Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Myasthenia Gravis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Myasthenia Gravis Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Myasthenia Gravis Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Intravenous Immune Globulins
  • Anticholinesterases
  • Immunosuppressants
Applications
  • Hospitals
  • Clinics
Companies covered
  • Alexion Pharmaceuticals
  • Bausch Health
  • Catalyst Pharmaceuticals
  • CSL
  • Curavac
  • Cytokinetics
  • F. Hoffmann-La Roche
  • Flamel Technologies
  • Galencia
  • GlaxoSmithKline
  • Grifols
  • Lupin Pharmaceuticals
  • Mitsubishi Tanabe Pharma
  • Pfizer
  • Novartis
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Myasthenia Gravis Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Myasthenia Gravis Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Myasthenia Gravis Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Myasthenia Gravis Drugs Market Dynamics
  1. 2.1 Myasthenia Gravis Drugs Industry Trends
  2. 2.2 Myasthenia Gravis Drugs Industry Drivers
  3. 2.3 Myasthenia Gravis Drugs Industry Opportunities and Challenges
  4. 2.4 Myasthenia Gravis Drugs Industry Restraints
3 Myasthenia Gravis Drugs Market by Company
  1. 3.1 Global Myasthenia Gravis Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Myasthenia Gravis Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Myasthenia Gravis Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Myasthenia Gravis Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Myasthenia Gravis Drugs Company Ranking (2024-2026)
  6. 3.6 Global Myasthenia Gravis Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Myasthenia Gravis Drugs Company Product Type and Application
  8. 3.8 Global Myasthenia Gravis Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Myasthenia Gravis Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Myasthenia Gravis Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Myasthenia Gravis Drugs Market by Type
  1. 4.1 Myasthenia Gravis Drugs Type Introduction
  2. 4.1.1 Intravenous Immune Globulins
  3. 4.1.2 Anticholinesterases
  4. 4.1.3 Immunosuppressants
  5. 4.2 Global Myasthenia Gravis Drugs Sales Volume by Type
  6. 4.2.1 Global Myasthenia Gravis Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Myasthenia Gravis Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Myasthenia Gravis Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Myasthenia Gravis Drugs Sales Value by Type
  10. 4.3.1 Global Myasthenia Gravis Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Myasthenia Gravis Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Myasthenia Gravis Drugs Sales Value Share by Type (2021-2032)
5 Myasthenia Gravis Drugs Market by Application
  1. 5.1 Myasthenia Gravis Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.2 Global Myasthenia Gravis Drugs Sales Volume by Application
  5. 5.2.1 Global Myasthenia Gravis Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Myasthenia Gravis Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Myasthenia Gravis Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Myasthenia Gravis Drugs Sales Value by Application
  9. 5.3.1 Global Myasthenia Gravis Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Myasthenia Gravis Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Myasthenia Gravis Drugs Sales Value Share by Application (2021-2032)
6 Myasthenia Gravis Drugs Regional Sales and Value Analysis
  1. 6.1 Global Myasthenia Gravis Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Myasthenia Gravis Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Myasthenia Gravis Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Myasthenia Gravis Drugs Sales by Region (2027-2032)
  5. 6.3 Global Myasthenia Gravis Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Myasthenia Gravis Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Myasthenia Gravis Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Myasthenia Gravis Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Myasthenia Gravis Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Myasthenia Gravis Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Myasthenia Gravis Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Myasthenia Gravis Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Myasthenia Gravis Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Myasthenia Gravis Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Myasthenia Gravis Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Myasthenia Gravis Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Myasthenia Gravis Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Myasthenia Gravis Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Myasthenia Gravis Drugs Sales Value Share by Country, 2025 VS 2032
7 Myasthenia Gravis Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Myasthenia Gravis Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Myasthenia Gravis Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Myasthenia Gravis Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Myasthenia Gravis Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Myasthenia Gravis Drugs Sales by Country (2027-2032)
  6. 7.4 Global Myasthenia Gravis Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Myasthenia Gravis Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Myasthenia Gravis Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Myasthenia Gravis Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Myasthenia Gravis Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Myasthenia Gravis Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alexion Pharmaceuticals
  2. 8.1.1 Alexion Pharmaceuticals Company Information
  3. 8.1.2 Alexion Pharmaceuticals Business Overview
  4. 8.1.3 Alexion Pharmaceuticals Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Alexion Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio
  6. 8.1.5 Alexion Pharmaceuticals Recent Developments
  7. 8.2 Bausch Health
  8. 8.2.1 Bausch Health Company Information
  9. 8.2.2 Bausch Health Business Overview
  10. 8.2.3 Bausch Health Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bausch Health Myasthenia Gravis Drugs Product Portfolio
  12. 8.2.5 Bausch Health Recent Developments
  13. 8.3 Catalyst Pharmaceuticals
  14. 8.3.1 Catalyst Pharmaceuticals Company Information
  15. 8.3.2 Catalyst Pharmaceuticals Business Overview
  16. 8.3.3 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Catalyst Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio
  18. 8.3.5 Catalyst Pharmaceuticals Recent Developments
  19. 8.4 CSL
  20. 8.4.1 CSL Company Information
  21. 8.4.2 CSL Business Overview
  22. 8.4.3 CSL Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 CSL Myasthenia Gravis Drugs Product Portfolio
  24. 8.4.5 CSL Recent Developments
  25. 8.5 Curavac
  26. 8.5.1 Curavac Company Information
  27. 8.5.2 Curavac Business Overview
  28. 8.5.3 Curavac Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Curavac Myasthenia Gravis Drugs Product Portfolio
  30. 8.5.5 Curavac Recent Developments
  31. 8.6 Cytokinetics
  32. 8.6.1 Cytokinetics Company Information
  33. 8.6.2 Cytokinetics Business Overview
  34. 8.6.3 Cytokinetics Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Cytokinetics Myasthenia Gravis Drugs Product Portfolio
  36. 8.6.5 Cytokinetics Recent Developments
  37. 8.7 F. Hoffmann-La Roche
  38. 8.7.1 F. Hoffmann-La Roche Company Information
  39. 8.7.2 F. Hoffmann-La Roche Business Overview
  40. 8.7.3 F. Hoffmann-La Roche Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 F. Hoffmann-La Roche Myasthenia Gravis Drugs Product Portfolio
  42. 8.7.5 F. Hoffmann-La Roche Recent Developments
  43. 8.8 Flamel Technologies
  44. 8.8.1 Flamel Technologies Company Information
  45. 8.8.2 Flamel Technologies Business Overview
  46. 8.8.3 Flamel Technologies Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Flamel Technologies Myasthenia Gravis Drugs Product Portfolio
  48. 8.8.5 Flamel Technologies Recent Developments
  49. 8.9 Galencia
  50. 8.9.1 Galencia Company Information
  51. 8.9.2 Galencia Business Overview
  52. 8.9.3 Galencia Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Galencia Myasthenia Gravis Drugs Product Portfolio
  54. 8.9.5 Galencia Recent Developments
  55. 8.10 GlaxoSmithKline
  56. 8.10.1 GlaxoSmithKline Company Information
  57. 8.10.2 GlaxoSmithKline Business Overview
  58. 8.10.3 GlaxoSmithKline Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 GlaxoSmithKline Myasthenia Gravis Drugs Product Portfolio
  60. 8.10.5 GlaxoSmithKline Recent Developments
  61. 8.11 Grifols
  62. 8.11.1 Grifols Company Information
  63. 8.11.2 Grifols Business Overview
  64. 8.11.3 Grifols Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Grifols Myasthenia Gravis Drugs Product Portfolio
  66. 8.11.5 Grifols Recent Developments
  67. 8.12 Lupin Pharmaceuticals
  68. 8.12.1 Lupin Pharmaceuticals Company Information
  69. 8.12.2 Lupin Pharmaceuticals Business Overview
  70. 8.12.3 Lupin Pharmaceuticals Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Lupin Pharmaceuticals Myasthenia Gravis Drugs Product Portfolio
  72. 8.12.5 Lupin Pharmaceuticals Recent Developments
  73. 8.13 Mitsubishi Tanabe Pharma
  74. 8.13.1 Mitsubishi Tanabe Pharma Company Information
  75. 8.13.2 Mitsubishi Tanabe Pharma Business Overview
  76. 8.13.3 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Mitsubishi Tanabe Pharma Myasthenia Gravis Drugs Product Portfolio
  78. 8.13.5 Mitsubishi Tanabe Pharma Recent Developments
  79. 8.14 Pfizer
  80. 8.14.1 Pfizer Company Information
  81. 8.14.2 Pfizer Business Overview
  82. 8.14.3 Pfizer Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Pfizer Myasthenia Gravis Drugs Product Portfolio
  84. 8.14.5 Pfizer Recent Developments
  85. 8.15 Novartis
  86. 8.15.1 Novartis Company Information
  87. 8.15.2 Novartis Business Overview
  88. 8.15.3 Novartis Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Novartis Myasthenia Gravis Drugs Product Portfolio
  90. 8.15.5 Novartis Recent Developments
  91. 8.16 Takeda
  92. 8.16.1 Takeda Company Information
  93. 8.16.2 Takeda Business Overview
  94. 8.16.3 Takeda Myasthenia Gravis Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Takeda Myasthenia Gravis Drugs Product Portfolio
  96. 8.16.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Myasthenia Gravis Drugs Value Chain Analysis
  2. 9.1.1 Myasthenia Gravis Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Myasthenia Gravis Drugs Sales Mode & Process
  6. 9.2 Myasthenia Gravis Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Myasthenia Gravis Drugs Distributors
  9. 9.2.3 Myasthenia Gravis Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst